Literature DB >> 29743371

Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.

Joshua W Wang1, Wai Hong Wu1, Tsui-Chin Huang1,2, Margaret Wong1, Kihyuck Kwak1, Keiko Ozato3, Chien-Fu Hung1,4,5, Richard B S Roden6,4,5.   

Abstract

To address how L2-specific antibodies prevent human papillomavirus (HPV) infection of the genital tract, we generated neutralizing monoclonal antibodies (MAbs) WW1, a rat IgG2a that binds L2 residues 17 to 36 (like mouse MAb RG1), and JWW3, a mouse IgG2b derivative of Mab24 specific for L2 residues 58 to 64. By Western blotting, WW1 recognized L2 of 29/34 HPV genotypes tested, compared to only 13/34 for RG1 and 25/34 for JWW3. WW1 IgG and F(ab')2 bound HPV16 pseudovirions similarly; however, whole IgG provided better protection against HPV vaginal challenge. Passive transfer of WW1 IgG was similarly protective in wild-type and neonatal Fc receptor (FcRn)-deficient mice, suggesting that protection by WW1 IgG is not mediated by FcRn-dependent transcytosis. Rather, local epithelial disruption, required for genital infection and induced by either brushing or nonoxynol-9 treatment, released serum IgG in the genital tract, suggesting Fc-independent exudation. Depletion of neutrophils and macrophages reduced protection of mice upon passive transfer of whole WW1 or JWW3 IgGs. Similarly, IgG-mediated protection by L2 MAbs WW1, JWW3, and RG1 was reduced in Fc receptor knockout compared to wild-type mice. However, levels of in vitro neutralization by WW1 IgG were similar in TRIM21 knockout and wild-type cells, indicating that Fc does not contribute to antibody-dependent intracellular neutralization (ADIN). In conclusion, the Fc domain of L2-specific IgGs is not active for ADIN, but it opsonizes bound extracellular pseudovirions for phagocytes in protecting mice from intravaginal HPV challenge. Systemically administered neutralizing IgG can access the site of infection in an abrasion via exudation without the need for FcRn-mediated transcytosis.IMPORTANCE At least 15 alpha HPV types are causative agents for 5% of all cancers worldwide, and beta types have been implicated in nonmelanoma skin cancer, whereas others produce benign papillomas, such as genital warts, associated with considerable morbidity and health systems costs. Vaccines targeting the minor capsid protein L2 have the potential to provide broad-spectrum immunity against medically relevant HPVs of divergent genera via the induction of broadly cross-neutralizing serum IgG. Here we examine the mechanisms by which L2-specific serum IgG reaches the viral inoculum in the genital tract to effect protection. Abrasion of the vaginal epithelium allows the virus to access and infect basal keratinocytes, and our findings suggest that this also permits the local exudation of neutralizing IgG and vaccine-induced sterilizing immunity. We also demonstrate the importance of Fc-mediated phagocytosis of L2 antibody-virion complexes for humoral immunity, a protective mechanism that is not detected by current in vitro neutralization assays.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Fc; FcRn; L2 protein; TRIM21; antibody-mediated protection; cross-protection; human papillomavirus; humoral immunity; monoclonal antibody; neutralizing antibodies

Mesh:

Substances:

Year:  2018        PMID: 29743371      PMCID: PMC6052307          DOI: 10.1128/JVI.00572-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

3.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

4.  In vivo mechanisms of vaccine-induced protection against HPV infection.

Authors:  Patricia M Day; Rhonda C Kines; Cynthia D Thompson; Subhashini Jagu; Richard B Roden; Douglas R Lowy; John T Schiller
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

5.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

7.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

8.  VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.

Authors:  Ebenezer Tumban; Julianne Peabody; Mitchell Tyler; David S Peabody; Bryce Chackerian
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

9.  Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model.

Authors:  Sabrina E Vinzón; Ilona Braspenning-Wesch; Martin Müller; Edward K Geissler; Ingo Nindl; Hermann-Josef Gröne; Kai Schäfer; Frank Rösl
Journal:  PLoS Pathog       Date:  2014-02-20       Impact factor: 6.823

10.  Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Authors:  Joshua W Wang; Subhashini Jagu; Chenguang Wang; Henry C Kitchener; Sai Daayana; Peter L Stern; Susana Pang; Patricia M Day; Warner K Huh; Richard B S Roden
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more
  11 in total

1.  Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.

Authors:  C Schellenbacher; B Huber; M Skoll; S Shafti-Keramat; R B S Roden; R Kirnbauer
Journal:  Vaccine       Date:  2019-05-27       Impact factor: 3.641

2.  Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Authors:  S M Bywaters; S A Brendle; J Biryukov; J W Wang; J Walston; J Milici; R B Roden; C Meyers; N D Christensen
Journal:  Virology       Date:  2018-08-28       Impact factor: 3.616

3.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

4.  Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.

Authors:  Sarah M Valencia; Athina Zacharia; Alexander Marin; Rebecca L Matthews; Chia-Kuei Wu; Breana Myers; Chelsea Sanders; Simone Difilippantonio; Reinhard Kirnbauer; Richard B Roden; Ligia A Pinto; Robert H Shoemaker; Alexander K Andrianov; Jason D Marshall
Journal:  Hum Vaccin Immunother       Date:  2021-02-11       Impact factor: 3.452

5.  A Mosquito AgTRIO Monoclonal Antibody Reduces Early Plasmodium Infection of Mice.

Authors:  Yu-Min Chuang; Xu-Dong Tang; Erol Fikrig
Journal:  Infect Immun       Date:  2021-11-01       Impact factor: 3.609

Review 6.  Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses.

Authors:  Matthew Zirui Tay; Kevin Wiehe; Justin Pollara
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

Review 7.  B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination.

Authors:  Priya R Prabhu; Joseph J Carter; Denise A Galloway
Journal:  Vaccines (Basel)       Date:  2022-05-25

8.  Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.

Authors:  Melinda Ahmels; Filipe C Mariz; Ilona Braspenning-Wesch; Sonja Stephan; Bettina Huber; Gabriele Schmidt; Rui Cao; Martin Müller; Reinhard Kirnbauer; Frank Rösl; Daniel Hasche
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

9.  Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies.

Authors:  Thach H Chu; Andrew R Crowley; Iara Backes; Cheryl Chang; Matthew Tay; Thomas Broge; Marina Tuyishime; Guido Ferrari; Michael S Seaman; Simone I Richardson; Georgia D Tomaras; Galit Alter; David Leib; Margaret E Ackerman
Journal:  PLoS Pathog       Date:  2020-02-24       Impact factor: 6.823

Review 10.  Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases.

Authors:  Pola Olczak; Richard B S Roden
Journal:  Vaccines (Basel)       Date:  2020-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.